XML 40 R33.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Stock Based Compensation (Tables)
3 Months Ended
Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Summary of Stock Option Activity

The following table summarizes stock option activity considering the conversion of Gyre Pharmaceuticals options to Gyre options to purchase shares of Gyre common stock upon completion of the Contributions:

 

 

 

Number of Shares
Underlying
Outstanding
Options

 

 

Weighted-
Average Exercise
Price

 

 

Weighted-
Average
Remaining
Contractual Term
(Years)

 

Outstanding — December 31, 2023

 

 

18,280,548

 

 

$

1.49

 

 

 

6.9

 

Options granted

 

 

1,866

 

 

$

17.86

 

 

 

 

Options exercised

 

 

(60,297

)

 

$

8.15

 

 

 

 

Options forfeited and cancelled

 

 

(3,622

)

 

$

22.85

 

 

 

 

Outstanding — March 31, 2024

 

 

18,218,495

 

 

$

1.46

 

 

 

6.7

 

Exercisable — March 31, 2024

 

 

18,205,433

 

 

$

1.46

 

 

 

6.7

 

 

 

Summary of Weighted Average Valuation Assumptions Used to Estimate Fair Value of Employee Stock Options Granted The fair value of employee stock options granted during the three months ended March 31, 2024 was estimated using the following weighted-average assumptions:

 

 

 

Three Months Ended March 31,

 

 

2024

 

 

2023

 

 

 

 

 

 

Risk-free interest rate (%)

 

 

4.2

%

 

n/a

Expected option life (in years)

 

 

6.0

 

 

n/a

Expected dividend yield (%)

 

 

%

 

n/a

Volatility (%)

 

 

84.3

%

 

n/a

Weighted average share price of the Company (USD per share)

 

$

17.86

 

 

n/a

 

Summary of Stock-Based Compensation Expense Recognized

Total stock-based compensation expense recognized was as follows (in thousands):

 

 

 

Three Months Ended March 31,

 

 

 

2024

 

 

2023

 

General and administrative

 

$

11

 

 

$

 

Total stock-based compensation expense

 

$

11

 

 

$